- Home
- NHI vs RARE Comparison
NHI vs RARE Comparison
Compare NHI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- RARE
- Stock Information
- Founded
- NHI 1991
- RARE 2010
- Country
- NHI United States
- RARE United States
- Employees
- NHI N/A
- RARE N/A
- Industry
- NHI Real Estate Investment Trusts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NHI Real Estate
- RARE Health Care
- Exchange
- NHI Nasdaq
- RARE Nasdaq
- Market Cap
- NHI 3.3B
- RARE 3.3B
- IPO Year
- NHI 1991
- RARE 2014
- Fundamental
- Price
- NHI $70.84
- RARE $37.14
- Analyst Decision
- NHI Buy
- RARE Strong Buy
- Analyst Count
- NHI 4
- RARE 15
- Target Price
- NHI $85.75
- RARE $90.53
- AVG Volume (30 Days)
- NHI 310.7K
- RARE 1.1M
- Earning Date
- NHI 08-05-2025
- RARE 07-31-2025
- Dividend Yield
- NHI 5.07%
- RARE N/A
- EPS Growth
- NHI 3.74
- RARE N/A
- EPS
- NHI 3.16
- RARE N/A
- Revenue
- NHI $343,615,000.00
- RARE $590,689,000.00
- Revenue This Year
- NHI $6.97
- RARE $18.94
- Revenue Next Year
- NHI $10.70
- RARE $28.93
- P/E Ratio
- NHI $22.51
- RARE N/A
- Revenue Growth
- NHI 7.49
- RARE 33.46
- 52 Week Low
- NHI $65.13
- RARE $29.59
- 52 Week High
- NHI $86.13
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- NHI 41.06
- RARE 52.29
- Support Level
- NHI $69.57
- RARE $36.01
- Resistance Level
- NHI $71.50
- RARE $40.19
- Average True Range (ATR)
- NHI 1.37
- RARE 1.47
- MACD
- NHI -0.05
- RARE 0.06
- Stochastic Oscillator
- NHI 35.47
- RARE 49.92
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.